Skip to content

Annexon ANNX Cash ratio

Cash ratio at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.6×-0.3×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
16.4×+15.8×
Omeros logo
OmerosOMER
0.0×
Vor Biopharma logo
Vor BiopharmaVOR
10.6×+7.6×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
2.1×-0.7×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×0.0×

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

Based on the most recent quarter.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's cash ratio?
Annexon (ANNX) reported cash ratio of 4.9× in Q1 2026.
How has Annexon's cash ratio changed year-over-year?
Annexon's cash ratio increased by 68.4% year-over-year, from 2.9× to 4.9×.
What is the long-term trend for Annexon's cash ratio?
Over 5 years (2020 to 2025), Annexon's cash ratio has grown at a -31.5% compound annual growth rate (CAGR), from 25.3× to 3.8×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.